



State of Wisconsin
2023 - 2024 LEGISLATURE

LRB-4215/1
JAM:cjs&emw

2023 ASSEMBLY BILL 753

December 6, 2023 - Introduced by Representatives GUSTAFSON, C. ANDERSON, BROOKS, EDMING, MURPHY, SAPIK, J. ANDERSON, BARE, CONSIDINE, EMERSON, JACOBSON, JOERS, OHNSTAD, ORTIZ-VELEZ, RATCLIFF, SHANKLAND, SINICKI and HAYWOOD, cosponsored by Senators JAMES, HESSELBEIN, AGARD, LARSON, ROYS and SPREITZER. Referred to Committee on Health, Aging and Long-Term Care.

1 **AN ACT** *to create* 20.285 (1) (qh), 20.285 (1) (qi), 25.14 (1) (a) 14m., 25.17 (1) (jw),
2 25.51 and 36.25 (16) of the statutes; **relating to:** creating a medicinal
3 psilocybin treatment fund and a pilot program to study the effects of medicinal
4 psilocybin treatment on patients with post-traumatic stress syndrome at the
5 University of Wisconsin–Madison and making an appropriation.

Analysis by the Legislative Reference Bureau

This bill creates a new separate nonlapsible trust fund designated as the medicinal psilocybin treatment fund and establishes a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome (PTSD).

The medicinal psilocybin treatment pilot program created by this bill must be established by the Board of Regents of the University of Wisconsin System at the University of Wisconsin–Madison in collaboration with that institution’s Transdisciplinary Center for Research in Psychoactive Substances and its School of Pharmacy. The individuals eligible to participate in the pilot program must be veterans who are 21 years of age or older and who suffer from treatment-resistant PTSD. Individuals who are law enforcement officers are not eligible to participate in the pilot program study. The psilocybin therapy provided by the pilot program must be provided through pathways approved by the federal Food and Drug Administration, and the research accomplished in the pilot program may be accomplished in conjunction with other medications approved by the federal Food

ASSEMBLY BILL 753

and Drug Administration. The board must ensure that no health information disclosed in the course of conducting the program contains personally identifiable information. The researchers conducting the program must create reports for the governor and the appropriate standing committees of the legislature regarding progress of the pilot program and the studies conducted as part of the program.

The medicinal psilocybin treatment fund created in this bill consists of donations, gifts, grants, bequests, moneys transferred from the general fund, and all earnings and other investment income of the fund. This trust fund is managed by the State of Wisconsin Investment Board. Moneys in the fund may be expended for the purpose for which any donation, gift, grant, or bequest is made and for the administration of the pilot program.

For further information see the state fiscal estimate, which will be printed as an appendix to this bill.

The people of the state of Wisconsin, represented in senate and assembly, do enact as follows:

1 **SECTION 1.** 20.005 (3) (schedule) of the statutes: at the appropriate place, insert
2 the following amounts for the purposes indicated:

2023-24 2024-25

3 **20.285 University of Wisconsin System**

4 (1) UNIVERSITY EDUCATION, RESEARCH AND PUBLIC
5 SERVICE

6 (qh) Medicinal psilocybin treatment

7 pilot program SEG A 100,000 -0-

8 **SECTION 2.** 20.285 (1) (qh) of the statutes is created to read:

9 20.285 (1) (qh) *Medicinal psilocybin treatment pilot program.* From the
10 medicinal psilocybin treatment fund, the amounts in the schedule for the operations
11 of the medicinal psilocybin treatment pilot program under s. 36.25 (16).

12 **SECTION 3.** 20.285 (1) (qi) of the statutes is created to read:

ASSEMBLY BILL 753

1 20.285 (1) (qi) *Medicinal psilocybin treatment pilot program donations, gifts,*
2 *grants, and bequests.* From the medicinal psilocybin treatment fund, all moneys
3 received from donations, gifts, grants, and bequests to the medicinal psilocybin
4 treatment pilot program under s. 36.25 (16) to carry out the purpose for which
5 received.

6 **SECTION 4.** 25.14 (1) (a) 14m. of the statutes is created to read:

7 25.14 (1) (a) 14m. The medicinal psilocybin treatment fund.

8 **SECTION 5.** 25.17 (1) (jw) of the statutes is created to read:

9 25.17 (1) (jw) The medicinal psilocybin treatment fund (s. 25.51).

10 **SECTION 6.** 25.51 of the statutes is created to read:

11 **25.51 Medicinal psilocybin treatment fund.** There is established a
12 separate nonlapsible trust fund designated as the medicinal psilocybin treatment
13 fund. The fund shall consist of all of the following:

14 (1) Donations, gifts, grants, and bequests deposited into the fund under s. 36.25
15 (16) (b).

16 (2) Moneys transferred under s. 36.25 (16) (c).

17 (3) All earnings and other investment income of the fund.

18 **SECTION 7.** 36.25 (16) of the statutes is created to read:

19 36.25 (16) **MEDICINAL PSILOCYBIN TREATMENT PILOT PROGRAM.** (a) 1. The board
20 shall establish at the University of Wisconsin-Madison in collaboration with that
21 institution's transdisciplinary center for research in psychoactive substances and its
22 school of pharmacy a pilot program to study the effects of medicinal psilocybin
23 treatment on patients with post-traumatic stress syndrome and related
24 comorbidities.

ASSEMBLY BILL 753**SECTION 7**

1 2. The individuals eligible for the pilot program under subd. 1. shall be
2 veterans, as defined by the board, who are 21 years of age or older and who suffer
3 from treatment-resistant post-traumatic stress syndrome. An individual who is a
4 law enforcement officer, as defined in s. 165.85 (2) (c), or a tribal law enforcement
5 officer, as defined in s. 165.85 (2) (g), may not participate in the pilot program under
6 subd. 1.

7 3. The pilot program under subd. 1. shall provide psilocybin therapy through
8 pathways approved by the federal food and drug administration.

9 4. The pilot program under subd. 1. may accomplish its research in conjunction
10 with other medications approved by the federal food and drug administration.

11 5. The board shall ensure that no health information disclosed by the pilot
12 program under subd. 1. contains personally identifiable information, as defined
13 under s. 19.62 (5).

14 6. On the first day of the 6th month beginning after the effective date of this
15 subdivision [LRB inserts date], and every 6 months thereafter while the pilot
16 program under subd. 1. continues, the board shall submit to the governor and to the
17 appropriate standing committees of the legislature under s. 13.172 (3) a report
18 prepared by the researchers conducting the pilot program that details the progress
19 of the pilot program's study.

20 7. Within 6 months of the completion of a study in the pilot program under subd.
21 1., the board shall submit to the governor and to the appropriate standing
22 committees of the legislature under s. 13.172 (3) a report prepared by the researchers
23 conducting the study detailing the results of the study and any recommendations for
24 legislation based on the study results.

